Fibrillin-1 assembly into microfibrils and elastic fiber formation involve interactions with glycosaminoglycans. We have used BIAcore technology to investigate fibrillin-1 interactions with heparin, and with heparin saccharides that are analogous to S-domains of heparan sulfate. We have identified four high affinity heparin binding sites on fibrillin-1, localized three of these sites, and defined their binding kinetics. Heparin binding to the fibrillin-1 N-terminus has particularly rapid kinetics. Hyaluronan and chondroitin sulphate did not interact significantly with fibrillin-1. Heparin saccharides with more than twelve monosaccharide units bound strongly to all four fibrillin-1 sites. Heparin did not inhibit fibrillin-1 N-and Cterminal interactions, or RGD-dependent cell attachment, but heparin and MAGP-1 competed for binding to the fibrillin-1 N-terminus, and heparin and tropoelastin competed for binding to a central fibrillin-1 sequence. By regulating these key interactions, heparin can profoundly influence microfibril and elastic fibre assembly.
Heparin has been shown, in affinity chromatography studies, to bind fibrillin-1 at the furin-processed C-terminus (13) . Heparin and heparan sulfate interacted in a calcium-independent manner to a large fibrillin-1 N-terminal fragment (Arg 45 -Thr 450 ) and to the C-terminal half of fibrillin-1 (Asp 1528 -Arg 2731 ), and in a calcium-dependent manner to a large central (Asp 1028 -Thr 1486 ) fragment of fibrillin-1 (9) . These heparan sulfate binding sites had a selective specificity for sulfated L-iduronaterich heparan sulfate. Addition of heparin or heparan sulfate to skin fibroblast cultures, and treatment with β-D-xylosides which inhibit the attachment of glycosaminoglycans to core proteins, inhibited fibrillin-1 microfibril deposition (9) . Sulfated heparan sulfate is also necessary for tropoelastin incorporation into ECM (14, 15) .
Heparan sulfate is an anionic linear polymer composed of 50-200 disaccharide units covalently attached to specific proteins, forming proteoglycans at the cell surface (syndecans, glypicans) and in the extracellular matrix (e.g. perlecan, agrin, collagen XVIII) (16) . Heparan sulfate chains are synthesized by enzymes that initially polymerise a chain of repeating glucuronic acid (GlcA) and N-acetylglucosamine (GlcNAc) units, which are then variously modified by N-and O-sulphation and uronate epimerization (17, 18) . These modifications occur in clusters, creating sulfation domains (S-domains) that form the principal recognition site for heparan sulfate binding proteins (17, 18) . Flanking the S-domains are regions of alternating N-sulphated and Nacetylated disaccharides, termed 'transition zones', the presence of which distinguishes HS from heparin which is highly modified along its entire length. Interactions between proteins and Sdomains can be dependent on a critical sequence of sulfate-modified sugars, e.g, fibroblast growth factor-2 (19) . In other cases, saccharide requirements for ligand binding reflect the length and preference for C-6 sulfation over C-2 or Nsulfation. The C-terminal endostatin fragment of collagen XVIII has been proposed to bind to S domains interrupted by one GlcNAc residue (20, 21) , and with specific requirements for sulfation at C-6 of amino sugars (22) . For other heparan sulfate-binding proteins especially multimeric cytokines such as interleukin-8, the region of heparan sulfate that interacts with the ligand is more extended, encompassing typically two S domains, including the intervening regions of lower sulfation (23) .
In vitro binding assays have revealed various other interactions between elastic fiberassociated molecules. N-and C-terminal fibrillin-1 interactions probably drive microfibril assembly (24, 25) . MAGP-1, decorin, biglycan and fibulin-5 interact with tropoelastin (7, 8, 10, 11, (26) (27) (28) . Ternary complexes of fibrillin-1, decorin and MAGP-1, and biglycan, elastin and MAGP-1 have been identified in vitro that could be important in elastic fiber formation (10, 11) . The fibrillin-1 N-terminus is particularly multifunctional since it can bind to itself and to the fibrillin-1 C-terminus (24, 25) , MAGP-1 (10, 28, 29) , LTBP-1 (30) , and versican (12) . Tropoelastin binds two internal fibrillin-1 sites and can be transglutaminase cross-linked to fibrillin-1 (29) .
In this study, we have used BIAcore technology to investigate fibrillin-1 interactions with glycosaminoglycans. We have mapped four high-affinity heparan sulfate binding sites on fibrillin-1 and defined their kinetics, established the binding efficacies of heparin fragments of defined lengths and showed how heparin binding to fibrillin-1 affects interactions with tropoelastin and MAGP-1 but not the homotypic fibrillin-1 interactions. We have also demonstrated that hyaluronan and chondroitin sulphate do not interact significantly with fibrillin-1. These data contribute significantly our understanding of how heparin, and by analogy its chemical analogue heparan sulfate, regulate microfibril and elastic fibre assembly.
Materials and Methods

Recombinant fibrillin-1 fragments and MAGP-1 -
Recombinant human fibrillin-1 fragments PF1 encoded by exons 1-11 (residues 1-489), PF2 encoded by exons 9-17 (residues 330-722), PF5 encoded by exons 18-25 (residues 723-1069), PF7 encoded by exons 24-30 (residues 952-1279), PF8 encoded by exons 30-38 (residues 1238-1605), PF9 encoded by exons 37-43 (residues 1528-2166), PF10 encoded by exons 41-52 (residues 1688-2165), PF11 encoded by exons 37-52 (residues 1528-2165), PF12 encoded by exons 50-58 (residues 2055-2443), PF13 encoded by exons 58-65 (residues 2402-2871) PF14 encoded by exons 33-40 (residues 1363-1688), and PF14 encoded by exons 33-40 (residues 1363-1688) (3), were expressed and purified in mg amounts using a mammalian episomal expression system and 293-EBNA cells, as described previously (25, 29, 31) (Fig. 1A and B ). Fragment PF14 is described in this manuscript for the first time. Fibrillin-1 fragments expressed in a similar system are correctly folded (9, 24) . PF1 fragments incorporating three separate Marfan syndromecausing point mutations, R62C, T101A and V449I (32), were also generated. Full-length human MAGP-1 was expressed in same mammalian expression system, purified under denaturing conditions using 8M urea, and refolded, as described previously (29) . Recombinant tropoelastin was generated as previously described (33, 34) .
Heparin and heparin saccharides -The heparin used was the sodium salt from porcine intestinal mucosa, with a molecular mass of approximately 3000 Da (Sigma Chem. Co., UK; #H3400). The heparin saccharides were not obtained from a commercial source, and were prepared by digestion of heparin with bacterial heparinase, as previously reported (35) . Three defined sized heparin saccharides were used: dp12, dp16 and dp24, which contain 12, 16 and 24 monosaccharides respectively. These fragments are chemical analogues of the sulphated domains (S-domains) of heparan sulfate; the domain structure of heparan sulfate is shown in Fig. 2 . The chondroitin 6-sulfate sodium salt used was from shark cartilage (Fluka, UK; #27045). The biotinylated hyaluronan was purchased from Sigma Chem. Co. UK (#B1557).
Biotinylation of heparin -Two methods of biotinylation were used in order to confirm the heparin saccharide interactions with fibrillin. The first approach was via oxidised cis-diol groups ( Fig. 2) (36) . Chondroitin sulphate, heparin, and heparin species dp12, dp16 and dp24, in 0.1mM solutions, were made up in 0.1M NaOAc, pH 5.5 (coupling buffer). To a volume of 100 µl was added the same volume of 20 mM sodium metaperiodate in coupling buffer. After 30 minutes on ice in the dark, 20 µl of 150mM glycerol was added to stop the oxidation, for 5 minutes on ice in the dark. The samples were dialysed into coupling buffer before the addition of Biotin-LC-Hydrazide (Pierce, UK) at a final concentration of 0.5 mM. After incubation for 2 hours at room temperature, the non-reacted biotin was removed by extensive dialysis into coupling buffer.
The second biotinylation approach involved coupling via the heparin reducing end, in two stages (36, 37) . First, reductive amination with ammonia, then biotin was coupled to the free amines (Fig. 2) . Heparin species dp12, dp16 and dp24, (0.1mg) were dissolved in 2M NH 4 Cl, in a volume of 100 µl. 2mg of NaCNBH 3 was added, and the mixture was heated at 70°C for 2 days. After cooling, the mixture was dialysed extensively into Dulbecco's phosphate buffered saline (PBS) (Cambrex UK). 10 µl of 3mg/ml Sulfo-NHS-LC-Biotin (Pierce, UK), was added and incubated overnight at 4 °C. The non-reacted biotin was then removed by further dialysis into 0.1M NaOAc pH 5.5. Heparin, heparin saccharides, hyaluronan and chondroitin sulfate binding analyses were performed using a panel of fibrillin-1 protein fragments encompassing full-length fibrillin-1, as analytes, at 100nM and a flow rate of 30 µl/min for 3 minutes. A high flow rate of 30 µl/min was used to minimize mass transport effects. After 2.5 minute dissociation, the chip was regenerated using 50mM NaOH, and 1M NaCl for 1 minute. The chip was then stabilized for 20 minutes using HBS-Ca, before the next injection was carried out. The analyte was simultaneously passed over a blank flow cell, and this baseline was subtracted from the experimental flow cell. None of the analytes was found to interact with the blank flow cell, however this control allowed bulk shifts caused by subtle differences in solvents to be eliminated. The maximum relative response value for each injection was calculated using the binding assay result wizard (BIAcore control software 3.2).
BIAcore 3000 binding analysis -
BIAcore 3000 kinetic analysis of molecular interactions -Kinetic analysis was performed using heparin and the heparin saccharides dp12, dp16 and dp24 immobilized to SA sensor chips, and fibrillin-1 fragments PF1, PF7, PF11 and PF13 that were shown in analyte screening to bind heparin and HS. Protein fragments were injected at concentrations ranging from 0.25-5 µg/ml at a flow rate of 30 µl/min. Samples were injected for 3 minutes, dissociated for 10 minutes, regenerated for 1 minute using 50mM NaOH, 1M NaCl, followed by 1 minute using HBS-Ca containing 800 mM NaCl and then stabilized for 10 minutes before the next injection. After subtraction of each response value from the blank cell, association and dissociation rate constants were determined by global data analysis. All curves were fitted using Two alternative methods were used for PF1 binding to heparin. PF1 binding to heparin was calculated independently using equilibrium analysis. The injection time was increased to 15 min and the dissociation time to 30 min. The equilibrium response was plotted against concentration, and non-linear regression using the equation for one site binding was used to calculate K D . To calculate association and dissociation constants for PF1, the observed rate constant k obs was calculated from the association phase using the 1:1 Langmuir association (k obs ) model (BIAevaluation 4.1, BIAcore AB). A secondary plot of k obs against concentration (C) allows k a and k d to be calculated using linear regression, using the equation k obs = k a C + k d .
The binding of PF1 mutants R62C, T101A and V449I were also analyzed against immobilized dp24, using the same methods. To investigate the kinetics of interactions between the PF1 mutants and MAGP-1, MAGP-1 was immobilized on the surface of a CM5 sensor chip via amine coupling, as previously described (29) , PF1 and PF1 mutants R62C, T101A and V449I were then injected at concentration ranges of 0.25-5 µg/ml at a flow rate 30 µl/min. Kinetic analysis was also performed on immobilized hyaluronan using versican G1 domain (kindly provided by Dr A. Day, MRC Immunochemistry Unit, Oxford, U.K.). Versican was injected at concentrations ranging from 1-5 µg/ml at a flow rate 30 µl/min. For a potential positive control for chondroitin-6-sulphate, binding of fibroblast growth factor (FGF) -1 and -2 was tested, but no significant binding was detected. However, chondroitin ABC lyase lowered the response level of the chondroitin sulfate immobilized flow cell, indicating cleavage may have taken place.
Inhibition assays using BIAcoreTo investigate the effects of MAGP-1 on binding of PF1 to dp24, kinetic analysis was performed using 1 µg/ml PF1 pre-incubated with 0.4-1200 nM MAGP-1 in HBS-Ca. MAGP-1 only 0.4-1200nM was separately passed over the sensor chip, as a control. These responses were then subtracted from the corresponding PF1/ MAGP-1 data. Analytes were injected over the sensor chip in the same manner as described for the kinetic studies. An inhibition curve was then plotted using the response value of each normalized curve, at the end of the association period. To investigate the effects of dp24 on the interaction of PF1 to MAGP-1, MAGP-1 was immobilized, using amine coupling, as described previously (29) . Kinetic analysis was carried out using 1 µg/ml and 5 µg/ml of PF1 pre-incubated with increasing concentrations of un-biotinylated dp24 0.4-4000nM; dp24 0.4-4000nM was separately passed over the sensor chip and then subtracted from the PF1/dp24 plots. An inhibition curve was plotted, as described above.
To investigate the effects of dp24 on the interaction of PF7 to tropoelastin, tropoelastin was immobilized, using amine coupling as described previously (29) . Kinetic analysis was carried out using 1 µg/ml and 5 µg/ml of PF7 pre-incubated with increasing concentrations of un-biotinylated dp24 0.4-4000nM, or with dp24 only (0.4-4000 nM). An inhibition curve was plotted, as described above.
Calcium dependency for fibrillin-1/ heparin interactions was determined by kinetic analysis, monitoring immobilized biotinylated dp24 binding to 5 µg/ml PF1, PF7 or PF11, in the presence of increasing concentrations of EDTA (0.01-10 mM). EDTA only sensorgrams were also plotted and subtracted from the FBN-1/EDTA sensorgrams. An inhibition curve was plotted, as described above.
Inhibition using solid phase binding assays -
Competition binding assays were also conducted using both non-biotinylated and biotinylated soluble proteins; biotinylation was carried out as described previously (29) . Flat bottomed microtiter plates were coated with PF1 and PF13, at 100nM in 50mM Tris pH7.4 0.1M NaCl, 1mM CaCl 2 (TBSa/CaCl 2 ), overnight at 4˚C. Nonspecific binding sites were then blocked with TBSa/CaCl 2 containing 4 % BSA, at room temperature for at least 2 hours. The plates were washed three times with TBSa/CaCl 2 /0.1% BSA and incubated with either 100 nM of biotinylated PF1 or PF13, which had been pre-incubated with heparin oligosaccharide dp24 (4-12000 nM) in TBSa/CaCl 2 , overnight at 4˚C. After a further three washes, plates were incubated with 1:200 dilution of extravidin peroxidase conjugate at room temperature for 15 minutes. Bound protein was quantified after four more washes by a colorimetric assay using 40mM 2,2'-azino-bis(3-ethyl-benzthiazoline-6-sulphonic acid) (ABTS) solution (Sigma Chemical Co., UK) for approximately 10-20 minutes at room temperature.
Plates were read at a wavelength of 405 Control wells with the first non-biotinylated soluble ligand not added, were incubated in TBSa/CaCl 2 only. For both methods, wells were then washed four times and the color developed. Any non-specific fibrillin-1 binding was detected by blocking wells before incubation with BSA only. All assays were performed in triplicate and repeated at least twice to confirm observed results. We used biotinylation as it is a widely used and sensitive molecular detection system.
Cell attachment assay -Cell attachment assays were performed as in (31) . Recombinant fibrillin-1 fragments PF14, PF9 and PF10 were diluted to 10µg/ml in PBS, absorbed onto wells of a 96 well microtitre plate for 1 hour, and unbound ligand was aspirated. Non-specific binding was blocked with 10mg/ml heat denatured BSA for 1 hour. Human dermal fibroblasts suspensions were prepared, counted and adjusted to 1x10 6 cells/ml. The BSA was aspirated, and 50µl of cell suspensions and 50µl of heparin sulfate (dp24) at double the desired concentration were added to the wells and incubated for 30min at 37ºC/5% CO 2 . To estimate cell number known numbers of cells were added to unblocked wells on the plate. Known cell number control wells were fixed with the addition of 10µl of 50% glutaraldehyde. Nonadherent cells were removed from the other wells by aspiration, then adherent cells were fixed with the addition of 100µl of 5% glutaraldehyde for 20 min. The wells were washed 3 times with 200µl of dH 2 O and cells were stained with 100µl of 0.1% (w/v) crystal violet in 0.2M MES pH5 for 1 hour. The crystal violet was aspirated, and excess stain was removed by four washes with 400µl of dH 2 O.
RESULTS
The dye was solubilised in 100µl of 10% (v/v) acetic acid, and the absorbance measured at 570nm. The absorbance from the known cell number wells was used to express data as percentage cell attachment.
A. DEFINING GLYCOSAMINOGLYCAN INTERACTIONS WITH FIBRILLIN-1 (i) Fibrillin-1 binding to heparin: specificity of GAG-interactions
Modelling of fibrillin-1 TB4-Heperin interaction -
The cbEGF-TB4-cbEGF structure was taken from the Protein Data Bank (code 1UZJ) (38) ; the file was edited to remove the first cbEGF domain, and the remaining TB4-cbEGF domains were used as the negative (non-heparan sulfate binding) control. The TB4-cbEGF structure was also used as a starting model to generate a TB5-cbEGF homology model. Modeling was performed in Quanta2000 (Accelerys) on a Silicon Graphics O2 R12,000 using the protein modelling modules. Partial charges were assigned in the ADT program (AutoDock tools) (39).
The structure of two heparin pentasaccharides that differ in the conformation of the iduronate residues ( 1 C 4 or 2 S 0 ) were generated from the Protein Data Bank (code 1HPN) (40) . Partial charges were assigned to atoms according to the PIM force field (41), allowed torsionable bonds were assigned in ADT.
BIAcore 3000 analysis was used to map the fibrillin-1 molecular regions that interact with heparin. Biotinylated polymeric heparin and heparin dp24 and immobilized on the surface of SA sensor chips. Fibrillin-1 fragments covering the entire molecule ( Fig. 1) were then each passed over the sensor chip surface at a concentration of 100 nM. Heparin and dp24 gave identical profiles (Fig. 3A,B) . Four non-overlapping fibrillin-1 fragments were found to bind to heparin and dp 24. The N-terminal fibrillin-1 fragment PF1 (encoded by exons 1-11) exhibited by far the highest binding response (~5000 response units [RU] for dp24). Internal fragment PF7 (encoded by exons 24-30) exhibited a response of over 200 RU that did not greatly depreciate after 2.5 min of dissociation.
Since overlapping fibrillin-1 fragments PF5 and PF8 did not bind heparin, this binding site must be within the four cbEGF-like domains encoded by exons 26-29. Fragments PF2, PF12 and PF14 did not interact with heparin. Of the four overlapping fibrillin-1 fragments PF9, PF10, PF11 and PF14, all except PF14 bound polymeric heparin and dp24. Thus, this heparin binding site is located in the overlap between PF9-11 (TB5 and the downstream cbEGF-like domain encoded by exons [41] [42] [43] . The C-terminal fragment PF13 also interacted with both heparin and dp24 (~100 RU). These data show that there are four heparin binding sites on fibrillin-1, and further localize the first three of these sites. Docking of the pentasaccharides was performed using the AutoDock 3.0 program (39) . The pentasaccharides were placed arbitrarily at two different positions either side of the TBcbEGF structure, 10Å from the protein surface. Grids of probe atom interaction energies and electrostatic potential were generated with a spacing of 0.375Å, using the AutoGrid program within the AutoDock suite. For each pentasaccharide, one simulation of 100 Lamarckian Genetic Algorithm runs was performed using 200 individuals and an energy evaluation number of 3 x 10 6 . Each run produced one binding solution and cluster analysis was performed at the end of each simulation. Solutions that were within 2Å root mean square deviation of each other, belonged to the same cluster, and clusters were ranked according to energy. Docking runs were performed with either the TB5-cbEGF model or the TB4-cbEGF structure.
When the fibrillin-1 fragments were passed over chips coated with hyaluronan or chondroitin 6-sulphate, no interactions with fibrillin-1 were detected. However, when versican G1 domain, a positive control, was passed over the hyaluronan sensor chip, an interaction was detected with a dissociation constant (K D ) of 11.0 nM. Thus, hyaluronan had been immobilized in a suitable manner to allow interactions with proteins. A direct positive control for chondroitin 6-sulfate binding could not be found, however cleavage of immobilized chondroitin sulfate chains by chondroitin ABC lyase was observed, indicating that it was immobilized in an active conformation. These results highlight that the fibrillin-1 interactions with heparin are specific.
(ii) Binding affinities of polymeric heparin and defined heparin saccarides for fibrillin- 1 The association (k a ) and dissociation (k d ) rate constants of the molecular interactions between polymeric heparin and fibrillin-1 protein fragments (PF1, PF7, overlapping PF9/ PF10/ PF11/ PF14, and PF13), and their dissociation constants (K D ), were determined by surface plasmon resonance (Fig. 4, Table 1 ). Heparin strongly bound the first three fibrillin-1 sites on fragments PF1, PF7 and PF9/PF10/PF11, all with low nM K D s, whilst the interaction of the Cterminal fragment PF13 had lower binding affinity.
Although binding kinetics for PF1 could be calculated using global fitting and the 1:1 binding equation, the resulting fit was poor compared to the other fibrillin-1 fragments. To calculate the K D for this interaction, equilibrium data were obtained by plotting a saturation binding curve. The K D was calculated to be 12.6 nM, which is a lower affinity than 3.9 nM calculated by global fitting, although of the same order. To calculate the k a and k d for PF1, the observed rate constant (k obs ) was determined using the separate k a /k d evaluation (BIAevaluation 4.1, BIAcore AB). A secondary plot of k obs against concentration could then be plotted, and linear regression using the equation k obs = k a C + k d .
In order to establish whether heparin oligosaccharide size influences binding to fibrillin-1, experiments were conducted using heparin saccharides dp12, dp16 and dp24, all of which were biotinylated by two comparable methods (cis-diol oxidation and reducing end) (36) . Kinetic data were obtained, using the appropriate models outlined above, for the binding of PF1, PF7 and PF11 to dp12, dp16 and dp24. PF11 was chosen from the four overlapping fragments (PF9/ PF10/ PF11/ PF14) around TB5, for kinetic analysis of heparin saccharide binding. The kinetic data are summarized in Table 2 , and Figs. 5 and 6. Only PF1 bound to dp12. Affinity to the three fibrillin-1 fragments increased with increasing saccharide chain length. PF1 had the highest affinity and PF7 the lowest affinity for dp24.
We also determined the binding affinities of the fibrillin-1 C-terminal fragment PF13 that had been fully furin processed, and PF13 which contained both processed and unprocessed fragments (3:1 ratio), using dp24 that had been biotinylated using the reducing end method (Fig.  5D) . The dissociation constants were 10.2 ± 0.6 nM for completely processed PF13 and 8.9 ± 2.2 nM for the mixture of processed and unprocessed PF13. As there was no significant difference between these K D s, the sequence after the furin cleavage site does not contribute to heparin binding. The dp24 interaction with PF13 was of lower affinity than its interactions with PF1, PF7 and PF11.
(iii) Effects of calcium on heparin -fibrillin-1 interactions
A previous study reported that 10 mM EDTA influences heparin binding to a large central fragment of fibrillin-1 but not to N-or Cterminal fragments (9) . We have investigated the calcium-dependence of the interactions between heparin and PF1, PF7 and PF11. These fibrillin-1 fragments (1 µg/ml) were incubated with increasing concentrations of EDTA (0.01-10 mM), prior to interaction with immobilized dp24. After subtraction of EDTA-only sensorgrams, the binding responses in all cases increased with increasing concentrations of EDTA up to 1 mM, but then sharply decreased up to 10 mM EDTA (Fig. 7C) To investigate whether homotypic fibrillin-1 interactions were affected by heparin, To gain further insights into the location of the fibrillin-1 PF1 heparin binding site, the potential effects of three classical Marfan syndrome disease-causing mutations (32) on PF1 binding to biotinylated dp24 were investigated (Table 3, Fig. 8 ). The binding kinetics of PF1 mutants R62C (mutation within domain encoded by exon 2) and V449I (mutation within domain encoded by exon 11) were similar to wild type PF1. However, PF1 mutant T101A (mutation within domain encoded by exon 3) bound dp24 with significantly lower affinity. This result implies that heparin binding involves the PF1 EGF-like domain encoded by exon 3.
solid phase inhibition assays were performed. In a recent study, we used solid-phase binding assays to show that PF1 and PF13 both interact strongly in a homotypic manner and with each other (25) . Here, heparin dp24 (4-12000 nM) was incubated with PF1 or PF13 (100 nM), before addition to either PF1 or PF13 pre-bound to the wells. Increasing concentrations of dp24 had no effect on the interaction of PF1 with PF13, or vice versa, and there was also no effect on the N-terminal PF1 -PF1 interaction (data not shown). Thus, heparin dp24, and by analogy S-domains of heparan sulphate in vivo, do not inhibit head-to-tail fibrillin-1 assembly.
(ii) Effects of heparin dp24 binding to fibrillin-1 PF1 on MAGP-1 binding Wild-type PF1 and the three PF1 mutants were also passed over immobilized MAGP-1 (Fig.  8) . These experiments showed that wild-type PF1 and the three mutants all bound MAGP-1 with similar affinities. Thus, although the PF1 binding sites for heparin and MAGP-1 are adjacent or overlapping, they are not identical.
We conducted inhibition assays to investigate whether MAGP-1 and heparin compete for binding to PF1. MAGP-1 binds close to the fibrillin-1 N-terminus (28, 29) . We investigated first whether MAGP-1 could inhibit the interaction of PF1 to dp24. Biotinylated DP24 was immobilized on the sensor chip, and MAGP-1 was initially passed over dp24, at concentrations ranging from 0.4-1200 nM, but no interaction was seen even at high concentrations (Fig. 7A inset) . PF1 (1 µg/ml, 20 nM) was then pre-incubated with MAGP-1 (0.4-1200 nM concentration range), and passed over the dp24 sensor chip surface. The binding response between PF1 and dp24 decreased with increasing concentrations of MAGP-1. The inhibition curve is shown in Fig. 7A . The EC 50 was calculated using GraphPad Prism 2.0 (nonlinear regression, sigmoidal dose response), and found to be 57.1 nM. Similar experiments were conducted to determine whether heparin dp24 could inhibit the interaction of PF1 and immobilized MAGP-1. dp24 was found not to interact with MAGP-1 at concentrations up to 4000 nM. dp24 (0.4-4000 nM) was then preincubated with PF1 at 1 µg/ml (20 nM), prior to analysis of binding to MAGP-1. Increasing concentrations of dp24 inhibited the response of PF1 with MAGP-1 (Fig. 7A) , and the EC 50 was calculated to be 59.9 nM. These data show that the heparin and MAGP-1 binding sites on PF1 are adjacent or overlapping, and that heparin strongly regulates MAGP-1 interactions with N-terminal fibrillin-1.
(iii) Effects of heparin dp24 binding to fibrillin-1 PF7 on tropoelastin binding
We previously showed that PF7 interacts with high affinity with tropoelastin (29) . Here, we investigated whether dp24 competes with tropoelastin for binding to PF7. For these experiments, tropoelastin was immobilized onto a CM5 sensor chip using amine coupling (29) . Initially, dp24 passed over the tropoelastin interacted strongly, with a dissociation constant of 1.0 nM (Fig. 7B) . The heparin dp24 fragment (0.4-4000 nM) was then pre-incubated with PF7 at 1 µg/ml (20 nM), prior to analysis of PF7 interactions with immobilized tropoelastin. When the dp24/ tropoelastin control binding curves were subtracted from the pre-incubated PF7/ dp24 binding to tropoelastin sensorgrams, it was found that the response decreased with increasing concentrations of dp24. The inhibition curves were plotted, (Fig. 7B) , and the EC 50 was calculated to be 5.3 nM. These experiments show that heparin regulates tropoelastin deposition on a fibrillin-1 template.
(C) INFLUENCE OF HEPARIN ON RGD-MEDIATED CELL ADHESION TO PF9/ PF11 (i) Effects of heparin dp24 on RGD-mediated cell adhesion to fibrillin-1.
Cell attachment assays were performed to study the effects of heparin on RGD-mediated cell adhesion. Cell binding to fibrillin-1 fragments PF14 (contains RGD but no heparin binding), PF9 (contains RGD and binds heparin) and PF10 (no RGD and binds heparin) was not affected by the presence of 125nM or 1.25µM heparin sulfate dp24 (data not shown).
(ii) Modeling of heparin docking to TB5 and downstream cbEGF-like domain
Modeling of the two domains that comprise the overlap region of PF9-PF11 which contains a high affinity heparin binding site, was conducted to investigate its potential docking mechanism. Two heparin pentasaccharides that differ in their conformation of the iduronate residues were used for docking to the model of fibrillin-1 TB5-cbEGF (Fig. 9) , which correspond to the overlap within fragments PF9-PF11 that binds heparin, and the non-heparin binding fibrillin-1 TB4-cbEGF structure (38) as a control. The pentasaccharides were placed at two different starting sites near the protein surface, and docking runs were performed followed by cluster analysis which revealed two potential heparin docking sites. Clusters with multiple members and negative docking energy are described. For TB5-cbEGF position 1, no clusters were found with the 2 S 0 conformation but clusters of 5 and 4 members were found with the 1 C 4 conformation which with further inspection were found to bind to the same site. Docking in position 2 yielded a cluster of 10 members for the 1 C 4 conformation and a cluster of 12 members for the 2 S 0 conformation, both these clusters bound to the same site. For the TB4-cbEGF control, no negative energy clusters were found for either heparin conformation.
All clusters were visualised using Quanta2000 and hydrogen bonds were calculated. The clusters with 5 and 4 members docked to the same site on TB5-cbEGF and bound in the interface between TB5 and the following cbEGF (site 1). The residues forming the pentasaccharide binding site were Arg1697, Asn1724, Arg1727, Arg1752 from the TB5 domain and Ser1788, Arg1790 from the cbEGF domain (Fig. 9A ). The clusters with 10 and 12 members bound towards the N-terminal region of the TB5 domain (site 2). The residues forming the pentasaccharide binding site were Arg1691, Arg1692, Asn1713, Asn1730, Lys1731 and Tyr1760 all from the TB5 domain (Fig. 9B) . For both heparin binding sites, the surface charge distribution was viewed using Grasp (42) (Fig. 9C and D) . The N-terminal site (site 2) is distinct from the TB5-cbEGF interface site (site 1), and is actually on the opposite face of the TB5 domain (Fig. 9E) .
DISCUSSION
We have investigated the nature of the specific fibrillin-1 interactions with heparin in order to determine how these glycosaminoglycans influence microfibril and elastic fiber assembly, and to obtain insights into the molecular basis of physiological heparan sulfate interactions with fibrillin-1. In these studies, we have used polymeric heparin and defined heparin saccharides that mimic the binding properties of the S-domains of heparan sulfate. We have shown that there are four distinct high affinity heparin binding sites on fibrillin-1, and have localised three of these sites to the N-terminus, the 'neonatal Marfan' region, and to a site downstream from the arg-gly-asp (RGD) cell attachment motif. A fibrillin-1 C-terminal heparin binding site was previously mapped adjacent to the furin-cleavage site (13) . Heparin binding affinity increases with increasing saccharide length, for all four fibrillin-1 sites. Although occupancy of the heparin binding site of the N-terminus of fibrillin 1 (PF1) did not inhibit its propensity for homophilic interaction, its capacity to interact with MAGP-1 was significantly reduced; likewise, MAGP-1 bound to PF1 reduced subsequent heparin binding to PF1. Heparin bound to the central fibrillin-1 sequence inhibited tropoelastin binding. Thus, in vivo, it is likely that the S-domains of heparan sulfate do not influence linear fibrillin-1 assembly, but regulate the association of MAGP-1 with microfibrils, and elastic fiber assembly. In future studies, it will be interesting to investigate the interactions of the four heparin binding regions of fibrillin-1 with authentic S-domains of heparan sulfate isolated from connective tissues to define the sulfation requirements for saccharide recognition at each site. Previous studies have suggested that small chondroitin sulfate proteoglycans may interact with microfibrils (10, 43) ; however, neither chondroitin sulfate nor hyaluronan bind directly to fibrillin-1.
The predominant disaccharide unit (approximately 80% of total disaccharides) of heparin used in this study was the trisulphated unit GlcNS,6S -IdoA,2S -this unit is found exclusively in the S-domains of heparan sulfate, although it is very rare to find S-domains composed entirely of trisulphated disaccharide sequences (18). Fibrillin-1 fragment affinity for heparin increased with saccharide chain length. Comparison of two biotinylation methods confirmed similar profiles of heparin saccharide binding to four fibrillin-1 fragments, and thus the specificity of these interactions.
Binding of heparin to the N-terminal fibrillin-1 fragment PF1 exhibited high affinity and rapid binding kinetics. The importance of protein conformation in this interaction is suggested since a specific Marfan N-terminal mutation (T101A, within the first EGF-like domain) markedly reduces the affinity of PF1 for heparin despite not involving a positively charged residue. The distinctive kinetics may depend, in part, on protein folding involving residues within or adjacent to this domain to create the glycosaminoglycan binding site. The eight arg and lys residues that occur in the mutated domain and its flanking domains are not clustered and, since the structure of PF1 is not known, the exact site of heparin binding is unclear although it is likely to be conformational rather than linear. Since the T101A mutation does not involve a charged residue, it is possible that T101 is critical for the correct folding of the EGF-like domain encoded by exon 3. In addition, the N-terminal region of fibrillin-1 has a tendency to form disulfide-bonded aggregates that could be important in lateral assembly (44) ; heparin binding may be enhanced by such multimerisation.
Using overlapping fibrillin-1 fragments (PF5, PF7 and PF8), we localized a second heparin binding site to four cbEGF-like domains encoded by exons 26-29 (residues 1070-1237), which are within the 'neonatal Marfan' region (5, 32) . We can exclude a previously predicted HS binding site (GKKGKT; residues1313-1318) (9) . There are nine arg and lys residues within these four cbEGF-like domains, seven of which are in domains encoded by exons 26 and 27. Four of these residues are on one face and three on the other (45) (Fig. 9A) , and could form heparin binding site(s).
The third heparin binding site was localized using overlapping fibrillin-1 fragments (PF9, PF10, PF11 and PF14) to the domains encoded by exons 41-43 (residues 1689-1807; TB5 and following cbEGF-like domain). This site is two domains downstream from the RGD-containing TB4 motif; however, bound heparin did not disrupt RGDdependent cell attachment. Modeling revealed two possible heparin docking sites; site-directed mutagenesis is now warranted to determine the usage of these sites.
The C-terminal HS binding site was previously localized to the last seventeen residues of mature processed fibrillin-1 which ends with the furin cleavage sequence RKRR (13) . We have shown that the presence or absence of the post-furin cleavage sequence has no effect on the ability of heparin to bind this fragment, but heparan sulfate may, in vivo, regulate the furin cleavage event.
Analysis of the kinetics of heparin binding to fibrillin-1 revealed that the N-terminal and central sites all bound heparin very strongly with low nM K D s, so these interactions are likely to be physiologically very significant. The very different kinetic parameters between the N-termimal PF1 fragment and the other peptides suggest different physiological roles. The rapid association of heparin with PF1 suggests that this is likely to be a more dynamic site, whereas interactions with PF7 and PF11 are "lazy" in that heparin both loads on and dissociates slowly. The C-terminal interaction is also likely to play an important role in fibrillin-1 biology. Implications of these kinetic studies for assembly and function are further discussed below.
A previous study indicated that 5 mM EDTA (heparin affinity chromatography) or 10 mM EDTA (solid phase assays) did not significantly affect heparin binding to the fibrillin-1 N-terminus, although it did influence an internal fibrillin-1 binding region that includes the PF7 sequence. Here, BIAcore analysis has revealed that increasing EDTA concentrations (1-10 mM) have complex effects but correlate with progressive reduction in heparin binding to N-terminal PF1, as well as the two internal sites identified here (PF7 and PF11). Thus, we conclude that calcium plays a role, directly or indirectly through conformation changes, in all three interactions.
The N-terminus of fibrillin-1 is highly interactive. We and others have shown that it strongly binds to itself and to the fibrillin-1 Cterminus (24, 25) , and to MAGP-1 (28, 29) . Here, we have shown that heparin does not inhibit its ability to bind homotypically or with the C-terminus, so heparin is unlikely to regulate linear fibrillin-1 assembly. Since heparin and MAGP-1 compete in a 1:1 manner for binding to the fibrillin1 N-terminal fragment PF1, their binding sites must be adjacent or overlapping. However, the Marfan mutation T101A, which reduces heparin affinity for PF1, does not affect MAGP-1 binding, so MAGP-1 and heparin binding sites are not identical. The ability of tropoelastin to bind fibrillin-1 (PF7) was also compromised by heparin; however, previous binding assays using overlapping fibrillin-1 fragments indicated that this tropoelastin binding site was within the domains encoded by exons 24 and 25 (29) ; thus, it is likely that tropoelastin and heparan sulfate sites are adjacent but not overlapping. These studies have shown that heparan sulfate may profoundly influence microfibril and elastic fibre assembly.
In vivo, heparan sulfate occurs in two main sites, as syndecan and glypican cell surface receptors (46) , and as perlecan in basement membranes. Fibrillin-1 interactions with heparan sulfate may be important at both sites. Interactions with cell surface receptors may profoundly influence microfibril and elastic fibre assembly. Fibrillin-1 binds integrin receptors α5β1 and αvβ3 (31, 47, 48) , whilst tropoelastin binds integrin αvβ3 and the elastin binding protein (49, 50) . It is possible that syndecan heparan sulfate chains may interact with newly-secreted fibrillin-1, and influence molecular alignment and multimerisation. Heparan sulfate proteoglycans with several heparan sulfate chains in close proximity on the core proteins might act as a template for assembly of fibrillin monomers using the N-domain as a docking site with fast association/dissociation from heparan sulfate chains. Previous studies have revealed that heparan sulfate, and sulfation, also play a key role in elastic fiber formation (14, 15) . Heparan sulfate can interact strongly with tropoelastin, which contains numerous charged lys residues, thereby influencing its potential to interact with fibrillin-1 and to form lysyl-derived crosslinks. A recurring theme is the colocalisation of fibrillin-1 microfibrils with basement membranes. Our previous structural studies of microfibrils allowed us to map the alignment of fibrillin-1 within mature beaded microfibrils (51) . The two central fibrillin-1 heparan sulfate binding sites map within the 'interbead' region of microfibrils and are likely to be available for interactions with heparan sulfate chains. However, N-and C-terminal binding sites may be within the bead structure and unavailable for interactions.
In summary, this study has provided important new insights into the molecular basis of heparin/ heparan sulfate interactions with fibrillin-1, shown how these glycosaminoglycans regulate fibrillin-1 interactions with MAGP-1 and tropoelastin, and demonstrate that they do not influence RGD-dependent cell attachment to fibrillin-1. 6 . Summary of kinetic data of fibrillin-1 binding to heparin and heparin oligosaccharides. Kinetic analysis using BIAcore was carried out on three different fibrillin fragments against heparin that was biotinylated using cis-diol oxidation (c/d) and reducing end (red) methods. Heparin saccharides of three chain lengths, dp12, dp16 and dp24, were used. The dissociation constant K D is shown on a log scale of fibrillin-1 protein fragments PF1 (black), PF7 (grey) and PF11 (white). The values are shown in Table 2 . N.B. = non binding. Fig. 7 . Inhibition of fibrillin-1 binding to MAGP-1 and tropoelastin by heparin dp24, and the effects of EDTA on fibrillin-1 interaction with dp 24. (A) Inhibition of fibrillin-1 PF1 interaction with heparin dp24 by MAGP-1 (■), PF1 (1 µg/ml) was incubated with MAGP-1 (0.4-1200 nM), before addition to immobilized dp24. Inhibition of PF1 with MAGP-1 by dp24, PF1 (1 µg/ml) (▲), was incubated with dp24 (0.4-4000nM) before addition to immobilized MAGP-1. The response difference was normalized to a percentage of the response of no inhibitor added. (B) Inhibition of fibrillin-1 PF7 with tropoelastin by dp24. PF7 (1 µg/ml) (▲), was incubated with dp24 (0.4-4000 nM) before addition to immobilized tropoelastin. The response curve of dp24 binding to tropoelastin was remove from the PF7/ dp24 curves and the response was plotted as a percentage of the response of no inhibitor added. (C) Effects of addition of EDTA to binding of PF1 (i), PF7 (ii) and PF11 (iii), EDTA (0.01-10 µM) incubated with fibrillin-1 (1 µg/ml) before addition to immobilized dp24. The response of EDTA only was subtracted from the response curves. Fig. 8 . Summary of kinetic data of fibrillin-1 PF1 mutants binding to heparin and MAGP-1. Kinetic analysis using BIAcore was carried out on fibrillin-1 PF1 mutants against HS dp24 biotinylated using cisdiol oxidation (c/d), and MAGP-1. The dissociation constant K D is shown on a log scale of fibrillin-1 protein fragments PF1 (black), PF1 R62C (light grey,) PF1 T101A (dark grey and PF1 V449I (white). The values are shown in Table 3 . Fig. 9 . Model of heparin -fibrillin-1 interaction. Docking prediction of heparin to fibrillin-1 domains TB5-cbEGF. (A,B) show close-up views of the two sites where heparin pentasaccharide is predicted to bind, the amino acids involved are labeled. At site 1 (A), heparin (green) is predicted to bind in the interface between the TB5 (grey) and the following cbEGF (orange). Site 2 (B) heparin (yellow) is predicted to bind at the N-terminus of TB5. (C,D) shows the grasp surface charge representation at these sites. (E) shows the distance between sites 1 and 2 indicates it is unlikely that a longer HS chain could straddle the two sites. (F) Shows a cartoon representation a pair cbEGFs encoded by exons 26 and 27, as determined by (45) . The charged residues are shown in blue, and are found to lie on either sides of the molecule. Table I .
Analysis of interactions between heparin and fibrillin-1 protein fragments by surface plasmon resonance
Surface plasmon resonance binding was performed as described in the experimental procedures. The kinetic parameters were derived from typical sensorgrams shown in Fig. 4 Table 2 .
Analysis of interactions between heparin saccharides and fibrillin-1 protein fragments by surface plasmon resonance
Surface plasmon resonance binding was performed as described in the experimental procedures. The sensorgrams for dp24-red are shown in figure 5 . 
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